0001209191-19-029480.txt : 20190513
0001209191-19-029480.hdr.sgml : 20190513
20190513195246
ACCESSION NUMBER: 0001209191-19-029480
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190513
FILED AS OF DATE: 20190513
DATE AS OF CHANGE: 20190513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Takeda Ventures, Inc.
CENTRAL INDEX KEY: 0001771657
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 19820133
BUSINESS ADDRESS:
STREET 1: 435 TASSO STREET
STREET 2: SUITE 300
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650-328-2900
MAIL ADDRESS:
STREET 1: 435 TASSO STREET
STREET 2: SUITE 300
CITY: PALO ALTO
STATE: CA
ZIP: 94301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD
CENTRAL INDEX KEY: 0001395064
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 19820134
BUSINESS ADDRESS:
STREET 1: 1-1, DOSCHOMACHI 4-CHOME
CITY: CHUO-KU, OSALCA 540-8645
STATE: M0
ZIP: 00000
MAIL ADDRESS:
STREET 1: 1-1, DOSCHOMACHI 4-CHOME
CITY: CHUO-KU, OSALCA 540-8645
STATE: M0
ZIP: 00000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Takeda Pharmaceuticals International AG
CENTRAL INDEX KEY: 0001688140
STATE OF INCORPORATION: V8
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 19820135
BUSINESS ADDRESS:
STREET 1: THURGAUERSTRASSE 130
STREET 2: GLATTPARK-OPFIKON
CITY: ZURICH
STATE: V8
ZIP: 8152
BUSINESS PHONE: 41-44-555-10-00
MAIL ADDRESS:
STREET 1: THURGAUERSTRASSE 130
STREET 2: GLATTPARK-OPFIKON
CITY: ZURICH
STATE: V8
ZIP: 8152
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Takeda Pharmaceuticals U.S.A., Inc.
CENTRAL INDEX KEY: 0001716229
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 19820136
BUSINESS ADDRESS:
STREET 1: ONE TAKEDA PARKWAY
CITY: DEERFIELD
STATE: IL
ZIP: 60015
BUSINESS PHONE: 2245546500
MAIL ADDRESS:
STREET 1: ONE TAKEDA PARKWAY
CITY: DEERFIELD
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cortexyme, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-13
0
0001662774
Cortexyme, Inc.
CRTX
0001771657
Takeda Ventures, Inc.
435 TASSO STREET, SUITE 300
PALO ALTO
CA
94301
0
0
1
0
0001395064
TAKEDA PHARMACEUTICAL CO LTD
1-1, NIHONBASHI-HONCHO 2-CHOME
CHUO-KU
TOKYO
M0
103-8668
JAPAN
0
0
1
0
0001688140
Takeda Pharmaceuticals International AG
THURGAUERSTRASSE 130
8152 GLATTPARK-OPFIKON
ZURICH
2M
GERMANY
0
0
1
0
0001716229
Takeda Pharmaceuticals U.S.A., Inc.
ONE TAKEDA PARKWAY
DEERFIELD
IL
60015
0
0
1
0
Common Stock
2019-05-13
4
C
0
2679802
A
2679802
D
Series A Redeemable Convertible Preferred Stock
2019-05-13
4
C
0
2360071
0.00
D
Common Stock
2360071
0
D
Series B Redeemable Convertible Preferred Stock
2019-05-13
4
C
0
319731
0.00
D
Common Stock
319731
0
D
The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.
Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.
These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
/s/ Christopher Lowe, as Attorney-in-Fact for Takeda Ventures, Inc.
2019-05-13
/s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceutical Company Limited
2019-05-13
/s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceuticals International AG
2019-05-13
/s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceuticals U.S.A., Inc.
2019-05-13